tradmap

STOK Earnings Stoke Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$3 -$1 $0 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $92M $184M 2018 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$105M -$52M $0 2018 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 $0 $2 $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
EPS
Revenue (quarterly)
$0 $79M $159M Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Revenue
Net income (quarterly)
-$62M $26M $113M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income

Reported EPS history

1–25 of 25
Q2 20262026-06-30-0.932026-08-0310-Q
Q1 20262026-03-31-0.792026-05-0710-Q
Q4 2025 (derived)2025-12-31-0.972026-03-1610-K
FY 20252025-12-31-0.122026-03-1610-K
Q3 20252025-09-30-0.652025-11-0410-Q
Q2 20252025-06-30-0.402025-08-1210-Q
Q1 20252025-03-311.902025-05-1310-Q
Q4 2024 (derived)2024-12-31-0.152025-03-1810-K
FY 20242024-12-31-1.652025-03-1810-K
Q3 20242024-09-30-0.472024-11-0510-Q
Q2 20242024-06-30-0.462024-08-0710-Q
Q1 20242024-03-31-0.572024-05-0610-Q
Q4 2023 (derived)2023-12-31-0.612024-03-2510-K
FY 20232023-12-31-2.382024-03-2510-K
Q3 20232023-09-30-0.552023-11-0710-Q
Q2 20232023-06-30-0.692023-08-0710-Q
Q1 20232023-03-31-0.532023-05-0410-Q
Q4 2022 (derived)2022-12-31-0.652023-03-0610-K
FY 20222022-12-31-2.602023-03-0610-K
Q3 20222022-09-30-0.662022-11-1410-Q
Q2 20222022-06-30-0.632022-08-0810-Q
Q1 20222022-03-31-0.66——
FY 20212021-12-31-2.34——
Q3 20212021-09-30-0.60——
Q2 20212021-06-30-0.60——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.